AACE would like to acknowledge and thank the following companies for their generous support of all non-CME activities.
Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc., is a development and commercialization company focused on transforming serious cardiometabolic lipid disorders. Akcea’s portfolio spans multiple targets and disease states, including both rare and more common lipid disorders, using advanced RNA-targeted antisense therapeutics. www.akceatx.com
Novo Nordisk, a global health care company, has been committed to discovering and developing innovative medicines to help people with serious chronic conditions lead longer, healthier lives with fewer limitations. We’re working toward a future where fewer people get chronic diseases, everyone is diagnosed, and all patients receive adequate treatment.
Veracyte, a leading genomic diagnostics company, develops the Afirma Genomic Sequencing Classifier. The test combines RNA sequencing data with machine learning to reclassify indeterminate thyroid nodules as benign and help clinicians reduce overtreatment. Since the commercial introduction of Afirma in 2011, Veracyte has performed over 100,000 genomic tests, and estimates it has saved more than 40,000 patients from unnecessary thyroid surgery. The Afirma classifier is included in most leading clinical guidelines and is covered as medically necessary by Medicare and all of the major U.S. health plans. The new Afirma Xpression Atlas is the company’s platform for using RNA sequencing to extract extensive genomic data – including gene expression, variants and fusions – from thyroid cytology samples.
At Eisai Inc., human health care (hhc) is our goal. We give our first thoughts to patients and their families and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, and marketing capabilities. Our key areas of focus include oncology and neurology (dementia-related diseases and neurodegenerative diseases). To learn more about Eisai Inc., please visit us at www.eisai.comUS and follow us on Twitter and LinkedIn.